Literature DB >> 10320094

Angiogenic factors in laryngeal carcinomas: do they have prognostic relevance?

M Burian1, C Quint, C Neuchrist.   

Abstract

Angiogenesis is a cascade-like mechanism essential for tumour growth and metastasis. Recently developed inhibitors of angiogenesis have already proven their benefit in anticancer treatment. Therefore the existence of angiogenic molecules in individual tumours is of major interest. The factors most frequently contributing to angiogenesis are basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and some matrix metalloproteinases (MMPs). In order to evaluate the prognostic significance of these molecules we investigated the distribution pattern of VEGF, bFGF, MMP-2 and MMP-9 in 41 laryngeal carcinomas using immunohistochemical methods. The results were correlated with clinicopathological parameters, i.e. T and N stage, histological grading, freedom from disease, overall survival and microvessel density (MVD). Only VEGF revealed a correlation with MVD (p = 0.01) and a weak association with histological grading (p = 0.06). Even though there is controversy about published data on the prognostic relevance of angiogenic factors, our results suggest that the factors examined in this study are not suitable for prognosis in larynx cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320094     DOI: 10.1080/00016489950181846

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  9 in total

1.  Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; P E Thorpe; R A Brekken; S Konstantinos; G Fountzilas; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  MMP-2 expression in 102 patients with glottic laryngeal cancer.

Authors:  Antony Mallis; Afshin Teymoortash; Nicholas S Mastronikolis; Jochen A Werner; Theodoros A Papadas
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-11       Impact factor: 2.503

3.  Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance.

Authors:  Sei Young Lee; Sung Yoon Park; Se-Heon Kim; Eun Chang Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-05-31       Impact factor: 3.372

4.  Size, shape, structure, and direction of angiogenesis in laryngeal tumour development.

Authors:  J Laitakari; V Näyhä; F Stenbäck
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

5.  Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma.

Authors:  Shu Zheng; Ming-Yong Han; Zuo-Xiang Xiao; Jia-Ping Peng; Qi Dong
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

6.  Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.

Authors:  H Mineta; K Miura; T Ogino; S Takebayashi; K Misawa; Y Ueda; I Suzuki; M Dictor; A Borg; J Wennerberg
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

7.  Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas.

Authors:  K I Wijffels; J H Kaanders; P F Rijken; J Bussink; F J van den Hoogen; H A Marres; P C de Wilde; J A Raleigh; A J van der Kogel
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

8.  CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma.

Authors:  Anke Schlüter; Patrick Weller; Oliver Kanaan; Ivonne Nel; Lukas Heusgen; Benedikt Höing; Pia Haßkamp; Sebastian Zander; Magis Mandapathil; Nina Dominas; Judith Arnolds; Boris A Stuck; Stephan Lang; Agnes Bankfalvi; Sven Brandau
Journal:  BMC Cancer       Date:  2018-03-09       Impact factor: 4.430

Review 9.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.